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Abstract
Aortic valve stenosis is the most clinically relevant valvular heart disease in the elderlies. Surgical aortic valve 
replacement (SAVR) represented, for decades, the standard of care for the treatment of severe aortic stenosis. Although 
SAVR still represents a valid option in this clinical scenario, transcatheter aortic valve implantation proved to be superior 
to medical therapy and comparable to SAVR in several randomized trials in patients at high or intermediate operative 
risk. At the same time, the growing aging population carrying on greater morbidities and high risk profiles has led to 
the development of minimally invasive technologies, as rapid deployment aortic valve replacement or Sutureless, to 
minimize surgical impact on patients. The Heart Team is nowadays tasked to determine the best option tailored for each 
patient considering patient-related factors and mastering all the surgical options in terms of both different techniques 
and types of available valves. Nevertheless, some open issues need to be already answered as: which has the longest 
durability, which the lower complication rate and the lower overall mortality. The aim of this review is to briefly resume 
the main features of these different options and explore what kind of open questions these newer-generation prosthetic 
valves and delivery devices carry.
Keywords: Aortic valve surgery, aortic valve stenosis, cardiac surgery, sutureless, transcatheter aortic valve implantation, new-
generation devices, minimally invasive technologies
INTRODUCTION
Aortic valve stenosis is the most clinically relevant valvular heart disease in the elderly people with a 
prevalence of 21%-26% in the elderly above 65 years of age and it increases with age, determining prognosis 
worsening after symptoms occurrence[1]. Surgical aortic valve replacement (SAVR) has represented, for 
decades, the standard treatment for patients with symptomatic and severe aortic stenosis, resulting in relief 
of symptoms, in a significant improvement of clinical outcome and in an improved survival. Although SAVR 
still represents a valid option in the setting of aortic valve stenosis, transcatheter aortic valve implantation 
(TAVI) proved to be superior to medical therapy and comparable-non inferior to SAVR in several 
randomized trials as well as in registries[2-4]. Following its introduction in 2002, with the first case performed 
in Rouen by Cribier et al.[2], TAVI has become an established treatment for patients with severe symptomatic 
aortic stenosis deemed inoperable or at high risk for conventional surgery. About 300,000 procedures have 
been performed worldwide with the first and second-generation CE-marked devices: Medtronic CoreValve® 
(Medtronic, Minneapolis, MN, USA) and Edwards SAPIENTM/SAPIEN XTTM (Edwards Lifesciences, Irvine, 
CA, USA) with an annual compound growth rate of 40%[5]. Due to an overall increased experience and 
the progressing technology in transcatheter valve systems[6], TAVI has been proposed and used in patients 
who are at intermediate and even low risk. The analysis of the Cohort A of the randomized trial PARTNER 
2 showed that TAVR was non-inferior to surgical aortic-valve replacement in terms of primary end-point 
of death or disabling stroke[7]. Therefore, recently published European guidelines[8] has reinforced TAVI 
recommendation in intermediate risk patients (class Ib, level of evidence B). Moreover the growing aging 
population, characterized by greater co-morbidities and risk profiles has led to the development of minimally 
invasive technologies[9] to reduce surgical impact on patients. An increasing number of surgeons are now 
endorsing minimally invasive aortic valve replacement through the sutureless valve technology (or rapid 
deployment valve). With this new emerging technology, TAVI, reasonable issues arise in comparison with 
surgical techniques and need to be answered: (1) which has the longest durability; (2) which encompasses the 
lower complication rate; and (3) the lower overall mortality.
SURGICAL AND INTERVENTIONAL APPROACHES
Patients usually can be scheduled to undergo a SAVR through conventional full midline sternotomy or mini- 
access according to the surgeon’s discretion and/or patients characteristics. In these two settings, patients 
can receive either a conventional stented or sutureless prosthesis. Compared with conventional surgery, 
minimally invasive access can provide shorter hospital stay, improve postoperative respiratory function and 
reduces postoperative pain, blood loss and blood transfusions thanks to the lower invasiveness. Commons 
minimally invasive approaches are: the partial upper ministernotomy, the right anterior minithoracotomy, 
the right parasternal approach from the second to the fourth costal space and the transverse sternotomy. 
Surgical approach, minimally invasive or not, still represents the standard of care for several reasons: it 
has the longest follow up, it can be performed in younger patients, in patients with intermediate-low risk 
profile, in patients requiring combined cardiac procedures or a redo operation. Open-heart surgery allows 
controlled and accurate decalcification of aortic annulus and consequently a safe valve positioning under a 
direct visualization and with a major leaks control. In specific condition, also an aortic root enlargement can 
be performed with this approach. On the other hand, standard surgical intervention is a time-consuming 
procedure in term of cardio-pulmonary bypass (CPB), cross-clamp and myocardial ischemia times. Patients 
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at higher risk can easily experience the so-called CPB side effects embracing a sequelae of side effects 
involving several organs and apparatus[10]. Alternative minimally invasive options has led to “sutureless” 
or rapid deployment aortic valves (RD-AV), which avoid the placement and tying of sutures finally leading 
to shorter CPB time. Sutureless valves are biological pericardial prostheses that can be anchored to the 
aortic annulus with only three sutures. Three different prostheses has to date, been developed: 3F Enable 
(Medtronic, Minneapolis, USA - CE approval withdrawn), Perceval S (Sorin, Saluggia, Italy), and Intuity 
Elite (Edward Lifesciences, Irvine, USA). The 3F Enable and Perceval S sutureless prostheses have a nitinol 
metal frame and can be deployed and positioned with no sutures in the case of Perceval S valves and only 
one suture for the Enable 3F valves. The Intuity rapid deployment aortic valve prosthesis has a cloth-covered 
frame and it is implanted through a balloon catheter delivery system that expands the frame once it achieved 
the appropriate annular position. Three sutures are required in the case of the Edwards Intuity valve. This 
technique may lead to shorter cross-clamp and CPB times, with a smaller amount of related adverse side 
effects, shorter in-hospital stay and similar survival rates as compared with conventional AVR. Actually, 
the procedure time is operator-dependent and relates to the specific operator learning curve. The prosthesis 
is usually landed in an intranular position and this may lead to better hemodynamic performance. RD-AV 
need careful patient selection since they need symmetric sinus configuration for adequate fitting in order to 
avoid paravalvular leakage and they are not recommended in bicuspid aortic valves. On one hand, it is not 
recommended to entirely decalcify the aortic annulus since it can be useful for the anchorage and likewise 
it avoids paravalvular leaks; on the other hand, heavily calcified sinutubular junctions may require special 
caution in sizing and deployment stages. Risk of stroke still represents an open issue since there are no 
specific recommendations regarding anticoagulation regimen after RD-AV implantation and no data are 
available on the risk of thrombus formation because of the stent frame and leaflet designs.
Greater morbidities and high-risk profiles on the contemporary patient population have driven the 
development of percutaneous TAVI, delivered in a micro-invasive fashion, with no need of CPB neither 
cardioplegic induced cardiac arrest. TAVI procedures have dramatically increased worldwide even if this 
data did not result in a decrease of overall SAVR performed compared with prior years[11]. This means that 
a consistent part of patients currently treated with TAVI could not beneficiate any surgical options in the 
previous years, the so called “pre-TAVI era”. Although it proves to be a good and safe technique in patients 
at intermediate - high risk, there are several factors to consider for eligibility as: (1) native annulus size, since 
< 18 mm or > 29 mm precludes this procedure; (2) cardiac anatomy, necessary in the choice of implant and 
method of delivery; (3) left ventricular outflow size and shape; (4) porcelain aorta or horizontally placed 
aortic root, that may complicate a transfemoral delivery; (5) height of coronary artery ostia, to prevent 
incidental occlusion of the coronaries; (6) assessment of the peripheral arterial vessels, in terms of diameter, 
tortuosities, kinks, preexisting stents, aneurysms or thrombi.
In this setting, it is clear how an appropriate patient selection is the key of success for a good outcome. 
Nevertheless, there are still open issues in terms of possible complications that deserve to be considered: 
(1) risk of malpositioning, since some models can not be repositioned, retrieved or resheathed; (2) risk of 
annular rupture because of oversizing or over dilatation, even if this is an experience-related complication 
more than a limit of the technique itself; (3) atrioventricular conduction abnormalities requiring a 
postoperative permanent pacemaker (PPM), this complication ranges between 3%-8%[11]; (4) paravalvular 
leaks; (5) risk of stroke; (6) vascular and bleeding complications; (7) limited durability. 
Due to their multifaceted aspects, requiring several different evaluations by several different professionals, 
in the last years a new concept has emerged and gained increasing attention in the context of several 
procedures like complex coronary interventions and TAVR: the Heart Team.
The “Heart Team” should play a pivotal role in decision making, since most procedures entail a complex 
interplay of multispeciality & multi modality skills such as in the case of TAVI. The Heart Team is thus 
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tasked to determine the best option for each patient considering many patient related factors and mastering 
all the surgical options both in terms of different techniques and types of valves available. Hereafter we offer 
a summing up table of all the current options as listed below [Table 1].
DISCUSSION
Conventional surgical treatment of aortic valve stenosis still represents the standard of care that can be 
performed with excellent outcomes. The growing aging population, the increasing number of comorbidities 
and the higher score risk of a consistent part of patients have led to the introduction of novel opportunities 
both as interventional and as surgical approaches [TAVI vs. rapid deployment aortic valve replacement (RD-
AVR)]. The decision to schedule one of these options should be based on a multilevel evaluation that includes 
the assessment of patients’ frailty, anamnesis, anatomy and degree of atherosclerosis of the aorta and 
peripheral vessels. Data available on prostheses’ hemodynamic performance and patients’ clinical outcomes 
play a crucial role in the decision process of both, type of procedure and device selection. Over the latest 
years, many comparative studies and meta-analysis are emerging on this argument. 
Thanks to the analysis of the Cohort A of the randomized trial PARTNER 2[7], it is now clear that TAVI 
procedure is non-inferior to surgical standard aortic valve replacement in terms of primary end-point of 
death or disabling stroke in intermediate risk patients. In particular, transfemoral TAVI procedure showed 
less mortality rate than SAVR, compared to transapical TAVI that showed the same mortality rate and 
the same kind of complications[7,12]. Also a previous work of our group showed a similar survival after 
transcatheter or SAVR[13]. Takagi et al.[14] analyzed 8 studies comparing SAVR and TAVI in 4244 patients 
from 2010 and 2015 and compared results in terms of gained left ventricular ejection fraction (LVEF) and 
left ventricular mass (LVM). This meta-analysis suggests greater LVM improvement after AVR, which may 
be due to higher incidence moderate aortic regurgitation after TAVI. LVEF improvement seems to be the 
same between TAVI and SAVR; but in patients with low baseline LVEF (< 40%) the improvement may be 
grater after TAVI than after SAVR. Witberg et al.[15] made a systematic review and meta-analysis on the 
relative risks and benefits of TAVR vs. SAVR in patients who are at low surgical risk. TAVI and SAVR 
resulted equivalent in short-term mortality but, in intermediate term mortality, TAVI showed increasing 
mortality rates compared to SAVR suggesting that TAVI should not be performed in this population. The 
analysis of TAVI in the low surgical risk population (Shot Term Risk Calculator - STS < 4%) is currently 
under evaluation by three randomised controlled trials (RCTs): the PARTNER 3 (NCT02675114), Medtronic 
Table 1. Types of prosthesis available and main features
TAVI RD-AVR
Models SAPIEN 
XT
Edwards
SAPIEN
3
Edwards
Corevalve
Medtronic
Evolut R
Medtronic
Evolut
PRO
Medtronic
Allegra
NVT
Jena Valve
JenaValveTech
Portico
St Jude 
Med
Lotus
Boston 
Sc.
Perceval
LivaNova
Intuity
Edwards
Approach Femoral
Trans 
apical
Trans 
aortic
Femoral
Trans 
apical
Trans 
aortic
Femoral
Suxlavian/
axillar
Trans aortic
Femoral
Suxlavian/
axillar
Trans 
aortic
Femoral
Suxlavian/
axillar
Trans 
aortic
Femoral Transapical Femoral Femoral Trans aortic
(Full 
sternotomy 
or mini-
invasive 
fashion)
Trans aortic
(Full 
sternotomy 
or mini-
invasive 
fashion)
Introducer 16, 18, 
20
14, 16 Fr 18, 20 Fr 14, 16 Fr 16 Fr 18 Fr 32 Fr 18 Fr 18, 20 
Fr
-- --
Deployment Balloon Balloon Self Exp Self Exp Self Exp Self Exp Self Exp Self Exp Balloon Self Exp Balloon
Valve sizes 23, 26, 
29
23, 26, 
29
26, 29, 31 23, 26, 
29, 34
23, 26, 29 23, 27, 
31
23, 25, 27 23, 25 23, 25, 
27
S, M, L, XL
(19-27 mm)
19-27
Recaptable No No No Yes Yes Yes No Yes Yes Yes  No 
Recommend
No
Valve in 
valve
Yes Yes Yes Yes Yes No data No data Yes Yes -- --
TAVI: transcatheter aortic valve implantation; RD-AVR: rapid deployment aortic valve replacement
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transcatheter aortic valve replacement in low risk patients (NCT02701283), and NOTION 2 (NCT02825134) 
trials[16]. Tam et al.[17] conducted a cost utility analysis comparing TAVI and SAVR in intermediate risk 
patients with severe aortic stenosis and TAVI appeared to be also a cost - effective treatment not only in 
terms of absolute value but also in terms of perspective quality of life and re-hospitalization. Villablanca et al.[18] 
published a meta-analysis on long-term outcomes of TAVR vs. SAVR. Their analysis confirms the findings 
from RCTs about similar longterm mortality between SAVR and TAVR. TAVR showed higher incidence of 
PPM implantation, residual aortic regurgitation, and vascular complications; SAVR showed higher incidence 
of myocardial infarction. Incidence of stroke, atrial fibrillation and acute kidney injury were lower with 
TAVR, especially in the high-risk population. Lastly the risk of PPM implantation is similar in intermediate-
risk patients between both TAVR and SAVR.
Data published on the comparison between RD-AVR and SAVR underline the benefits of RD-AVR in terms 
of operative time reduction, CBP duration and increased effective orifice area and consequent lower post-
operative transvalvular gradient[19]. The most common complications reported in the case of RD-AVR are 
higher incidence of pacemaker implantation, postoperative stroke and residual aortic regurgitation[20], while 
the most common complications reported in the case of standard procedure tend to be exclusively surgery 
related as major bleeding or acute renal failure[21]. Totally in contrast to these previous studies, the German 
Aortic Valve Registry (GARY) recently analyzed a total of 22,062 patients who underwent isolated SAVR 
using SAVR or RD-AVR between 2011 and 2015[22]. GARY analysis demonstrated that the advantages carried 
by RD-AVR may not translate into effective benefits. Patients currently undergoing SAVR are at low - 
intermediate surgical risk, with consequent low expected complication rates, so low pacemaker rate is still a 
strong argument in favor of SAVR. According to the authors, there are no reasons for choosing RD-AVR and 
increasing the risk of a post-operative PPM implantation. In contrast to the previous studies, this analysis 
also showed significantly elevated post-operative transvalvular gradients in sutureless valves, independently 
of the implanted valve sizes. At last, many data exist regarding comparison between RD-AVR and TAVI 
even if they do not always stratify patients for surgical scoring risk, in consequence TAVI patients tend to 
have higher scores. Meco et al.[23] made a metanalysis of 6 studies including 1,462 patients (RD-AVR 731 
vs. TAVI 731) with similar operative risk (Euroscore1: 15.45 ± 9 RD-AVR vs. 15.58 ± 8.1 TAVI). Thirty days 
all cause mortality and complications as stroke, paravalvular regurgitation, vascular complications were 
significantly lower in RD-AVR. The rate of acute kidney injury and pacemaker implantation were similar. 
RD-AVR group required more transfusion. Mid term survival rates (at 1 or 2 years) were significantly better 
in RD-AVR. SAVR using sutureless valves may be associated with better early and mid-term outcomes 
compared with TAVI in high- or intermediate-risk patients; the authors found a 50% risk reduction in early 
all causes of death and a 65% and 62% risk reduction in 1- and 2-year mortality for TAVI[23]. Recently Shinn et al.[24] 
provided a meta analysis including 7 observational studies comprising 617 RD-AVR and 621 TAVI patients: 
early mortality was 2.5% and 5% respectively, post procedural paravalvular leak was lower in RD-AVR and 
post procedural stroke and need for pacemaker implantation were comparable between the two cohorts.
From several studies, it appears that post operative need for pacemaker implantation is similar in both 
techniques, TAVI seems to have lower transvalvular gradients but more common peri-prosthetic leaks and, 
in the end, RD-AVR seems to have lower mortality rates[25]. Finally, a large study from D’onofrio et al.[26] 
obseverd 2,177 patients (1,885 TAVI vs. 292 RD-AVR): they found similar incidence of 30-day and 1 year 
mortality rates, stroke, bleeding and myocardial infarction. Patients treated with TAVI showed less device 
success and more postoperative perivalvular leak, even if this was less evident in trans apical procedures. 
RD-AVR resulted in higher transaortic gradients, longer post operative length and similar pacemaker 
implantation rate[26].
CONCLUSION
The Heart Team is nowadays tasked to determine the best option for each patient considering patient related 
factors and cost effectiveness. The choice between surgical AVR vs. TAVR is based on multiple factors 
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including the surgical risk, patient frailty, comorbidities and also patient preferences. Since 2012, TAVR 
indications have been extended into groups of patients who are at intermediate to high risk; TAVR has also 
become the alternative to reoperation for those with bioprosthetic aortic valve degeneration. There are still 
few data on TAVI for patients < 75 years of age and for surgical low-risk patients, in whom SAVR remains 
the preferred approach since long-term durability data for TAVI prosthetic valves are still lacking. Moreover, 
younger patients often carry a bicuspid valve disease and this anatomic pattern may affect the results of 
TAVI. The past above cited trials excluded bicuspid valve patients. Surgical approach still plays a crucial role 
in all the combined procedures as concomitant severe coronary artery disease, concomitant ascending aorta 
disease or concomitant mitral and tricuspid valve disease. On the other side, longer follow up for both TAVI 
and RD-AVR are going to be needed, not only for the effective durability, but to clear risk of paravalvular 
leaks and pacemaker requirement, since they are likely to have greatest impact on low-risk and younger 
populations on life expectancy and they are currently being investigated in randomized trials. Another open 
issue is represented by anticoagulation regimen, since no specific recommendations exist on it and no data 
are available on the risk of thrombus formation because of the stent frame and leaflet designs.
In the end, the approval of a TAVR valve for lower STS SAVR risk population does not mean, by now, that 
TAVR is going to be the chosen procedure for any patient but this would certainly promote and encourage 
the scientific debate and future researches.
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